A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 810 participants.

Also called NCT01075282

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 810 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01075282
Other papers using this trial's data
  • Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2) Diabetes care, 2015-12 DOI, PubMed 26089386

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Argentina, Australia, Belgium, Brazil, Canada, Croatia, Czechia, France, Greece, Hungary, India, Italy, Mexico, Poland, Romania, Slovakia, South Korea, Spain, Sweden, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01075282. Randomized; no masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2012-05 (actual). Results posted on 2015-01-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
Acronym
AWARD-2
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin Glargine
Intervention (Drug)
LY2189265
Intervention (Drug)
Metformin
Intervention (Drug)
Glimepiride
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01075282
Content hash
e7c3690e99c0d9a10097589a0394c7f1b690390117fc44691813c7dc6e257220